Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine

S. J. Brown; W. J. Slizofski; S. Dadparvar

Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine

S. J. Brown, W. J. Slizofski, S. Dadparvar

Department of Radiology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Markedly altered biodistribution of [⁶⁷Ga]citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on [⁶⁷Ga]citrate scintigraphy.

Original language	English (US)
Pages (from-to)	115-117
Number of pages	3
Journal	Journal of Nuclear Medicine
Volume	31
Issue number	1
State	Published - 1990

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging

Cite this

@article{923f554c748e491b9e71fe0c06d7e16b,

title = "Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine",

abstract = "Markedly altered biodistribution of [67Ga]citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on [67Ga]citrate scintigraphy.",

author = "Brown, \{S. J.\} and Slizofski, \{W. J.\} and S. Dadparvar",

year = "1990",

language = "English (US)",

volume = "31",

pages = "115--117",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

TY - JOUR

T1 - Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine

AU - Brown, S. J.

AU - Slizofski, W. J.

AU - Dadparvar, S.

PY - 1990

Y1 - 1990

N2 - Markedly altered biodistribution of [67Ga]citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on [67Ga]citrate scintigraphy.

AB - Markedly altered biodistribution of [67Ga]citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on [67Ga]citrate scintigraphy.

UR - https://www.scopus.com/pages/publications/0025177296

UR - https://www.scopus.com/inward/citedby.url?scp=0025177296&partnerID=8YFLogxK

M3 - Article

C2 - 2295931

AN - SCOPUS:0025177296

SN - 0161-5505

VL - 31

SP - 115

EP - 117

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -

Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this